153 related articles for article (PubMed ID: 38570792)
1. Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies.
Campochiaro C; Farina N; De Luca G; Batani V; Trignani G; Vignale D; Palmisano A; Matucci-Cerinic M; Dagna L
Arthritis Res Ther; 2024 Apr; 26(1):79. PubMed ID: 38570792
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
Ahn GY; Suh CH; Kim YG; Park YB; Shim SC; Lee SH; Lee SS; Bae SC; Yoo DH
J Korean Med Sci; 2020 Sep; 35(38):e335. PubMed ID: 32989931
[TBL] [Abstract][Full Text] [Related]
3. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trial.
Bejan-Angoulvant T; Naccache JM; Caille A; Borie R; Nunes H; Ferreira M; Cadranel J; Crestani B; Cottin V; Marchand-Adam S;
Respir Med Res; 2020 Nov; 78():100770. PubMed ID: 32777737
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.
Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C
Front Immunol; 2022; 13():1051609. PubMed ID: 36578492
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
[TBL] [Abstract][Full Text] [Related]
7. Prevalent Drug Usage Practices in Adults and Children With Idiopathic Inflammatory Myopathies: Registry-Based Analysis From the MyoCite Cohort.
Mehta P; Rathore U; Naveen R; Chatterjee R; Agarwal V; Aggarwal R; Gupta L
J Clin Rheumatol; 2022 Mar; 28(2):89-96. PubMed ID: 35067505
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study.
Leclair V; Galindo-Feria AS; Dastmalchi M; Holmqvist M; Lundberg IE
Rheumatology (Oxford); 2019 Jul; 58(7):1214-1220. PubMed ID: 30690633
[TBL] [Abstract][Full Text] [Related]
10. Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies.
Janardana R; Amin SN; Rajasekhar L; Pinto B; Kodishala C; Selvam S; Shobha V
Rheumatology (Oxford); 2023 Mar; 62(3):1243-1247. PubMed ID: 35946502
[TBL] [Abstract][Full Text] [Related]
11. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
12. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.
Nalotto L; Iaccarino L; Zen M; Gatto M; Borella E; Domenighetti M; Punzi L; Doria A
Immunol Res; 2013 Jul; 56(2-3):362-70. PubMed ID: 23572427
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series.
Olivo Pallo PA; de Souza FHC; Miossi R; Shinjo SK
Adv Rheumatol; 2018 Oct; 58(1):34. PubMed ID: 30657093
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.
Huang W; Wang L; Xia J; Li W; Wang M; Yu J; Li Q; Wang B; Pan J; Du L; Ma J; Tan H; Chang X; Lu C; Zhao C; Lu J; Zhou L; ZhangBao J; Quan C;
Eur J Neurol; 2022 Aug; 29(8):2343-2354. PubMed ID: 35398950
[TBL] [Abstract][Full Text] [Related]
16. Performance of the new EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort.
Barsotti S; Dastmalchi M; Notarnicola A; Leclaire V; Dani L; Gheorghe K; Ekholm L; Bottai M; Tjärnlund A; Lundberg IE
Semin Arthritis Rheum; 2020 Jun; 50(3):492-497. PubMed ID: 32024593
[TBL] [Abstract][Full Text] [Related]
17. Comparison of rituximab efficacy in treatment-naive and refractory inflammatory myopathies: experiences from a tertiary care centre.
Manwatkar A; Naresh K; Mathew J; Nair AV; Goel R; Yadav B; Prakash JAJ; Das JK; Sivadasan A
Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38814804
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study.
Conticini E; d'Alessandro M; Grazzini S; Rizzo C; Fornaro M; Cameli P; Bennett D; Abbruzzese A; Camarda F; Lopalco G; Bergantini L; Falsetti P; Bargagli E; Iannone F; Guggino G; Chinoy H; Cantarini L; Frediani B
Clin Exp Rheumatol; 2023 Mar; 41(2):285-290. PubMed ID: 36861742
[TBL] [Abstract][Full Text] [Related]
19. Autoantigenic properties of the aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies.
Preger C; Notarnicola A; Hellström C; Wigren E; Fernandes-Cerqueira C; Kvarnström M; Wahren-Herlenius M; Idborg H; Lundberg IE; Persson H; Gräslund S; Jakobsson PJ
J Autoimmun; 2023 Jan; 134():102951. PubMed ID: 36470210
[TBL] [Abstract][Full Text] [Related]
20. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
